A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-27

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

NCT05669625

Varicella

ACTIVE_NOT_RECRUITING PHASE3

A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine

NCT03555071

Varicella

COMPLETED PHASE3

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

NCT05158777

Varicella

COMPLETED PHASE3

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

NCT05015686

Varicella

ENROLLING_BY_INVITATION PHASE3

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

NCT05150392

Varicella

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is aim to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy people 1 to 12 years of age.1200 healthy subjects aged 1-12 years were enrolled after their guardians passed the informed consent, inclusion and exclusion criteria screening in turn. Three batches were randomized in a 1:1: 1 ratio, with 400 subjects in each batch.All subjects received 1 dose of trial vaccine (Batch 1 or Batch 2 or Batch 3) and all were collected Blood samples were collected from subjects before vaccination, on Day 30 after vaccination for serum neutralizing antibody testing to evaluate immunogenicity, and Safety observations were performed until 6 months post-vaccination in all subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Varicella

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group1

Single subcutaneous injection of the investigational vaccine (0.5ml)

Group Type EXPERIMENTAL

Investigational live attenuated varicella vaccine (lot 1)

Intervention Type BIOLOGICAL

0.5ml/vial

Experimental Group2

Single subcutaneous injection of the investigational vaccine (0.5ml)

Group Type EXPERIMENTAL

Investigational live attenuated varicella vaccine (lot 2)

Intervention Type BIOLOGICAL

0.5ml/vial

Experimental Group3

Single subcutaneous injection of the investigational vaccine (0.5ml)

Group Type EXPERIMENTAL

Investigational live attenuated varicella vaccine (lot 3)

Intervention Type BIOLOGICAL

0.5ml/vial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational live attenuated varicella vaccine (lot 1)

0.5ml/vial

Intervention Type BIOLOGICAL

Investigational live attenuated varicella vaccine (lot 2)

0.5ml/vial

Intervention Type BIOLOGICAL

Investigational live attenuated varicella vaccine (lot 3)

0.5ml/vial

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 1 to 12 years on the day of enrollment ,male or female, and able to provide legal identity certificate.
* Subjects and/or guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent form.
* Axillary temperature ≤ 37.0 ° C on the day of enrollment.

Exclusion Criteria

* Previous vaccination against varicella (eg, varicella vaccine, measles + varicella vaccine).
* History of varicella or herpes zoster infection, or exposure to varicella/herpes zoster within 30 days of enrollment or suspected varicella/herpes zoster;
* Current use of salicylates (including salicylic acid, aspirin, diflunisal, p-aminosalicylic acid (sodium), salsalsalate, benorilate, etc.), or planned long-term use during the study.
* Febrile illness (axillary temperature ≥ 38.5 ° C) or use of antipyretic, analgesic, and anti-allergic drugs (eg, acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination.
* History of allergy to vaccine ingredients and excipients or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria.
* History of epilepsy, convulsions, or convulsions, or a family history of psychosis.
* Impaired immune function or has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases.
* Patients suffering from serious congenital malformations, genetic diseases, serious cardiovascular diseases, serious liver/kidney diseases, diabetes with complications, malignant tumors, severe malnutrition.
* Immunosuppressant therapy such as chronic oral or injectable glucocorticoid therapy (≥ 14 days at doses ≥ 2 mg/kg/day or ≥ 20 mg/day prednisone or equivalent prednisone dose) within 3 months prior to administration of trial vaccine or planned 30 days following administration, but not limited by topical use (eg, ointment, eye drops, inhalers, or nasal sprays).
* Receiving blood/blood-related products or immunoglobulins 3 months before vaccination or planning to use such products 30 days after vaccination.
* Vaccination with a live attenuated vaccine within 30 days or any vaccine within 14 days prior to vaccination.
* Absence of spleen or splenectomy due to any condition such as splenectomy.
* Patients with a history of thrombocytopenia or other coagulation disorders, which may cause contraindications to subcutaneous injection.
* Infectious, suppurative and allergic skin diseases.
* Participating in other investigational or non-registered product (drug, vaccine or device, etc.) clinical trials, or planning to participate in other clinical trials before the end of this clinical trial.
* Subject has any other factor that, in the judgment of the investigator, would make the subject unsuitable for participation in the clinical trial.

Minimum Eligible Age

1 Year

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes